A major problem in cancer research is the lack of a tractable model for delayed metastasis. Herein we show that cancer cells suppressed by SISgel, a gel-forming normal ECM material derived from Small Intestine Submucosa (SIS), in flank xenografts show properties of suppression and re-activation that are very similar to normal delayed metastasis and suggest these suppressed cells can serve as a novel model for developing therapeutics to target micrometastases or suppressed cancer cells. Co-injection with SISgel suppressed the malignant phenotype of highly invasive J82 bladder cancer cells and highly metastatic JB-V bladder cancer cells in nude mouse flank xenografts. Cells could remain viable up to 120 days without forming tumors and appeared much more highly differentiated and less atypical than tumors from cells co-injected with Matrigel. In 40% of SISgel xenografts, growth resumed in the malignant phenotype after a period of suppression or dormancy for at least 30 days and was more likely with implantation of 3 million or more cells. Ordinary Type I collagen did not suppress malignant growth, and tumors developed about as well with collagen as with Matrigel. A clear signal in gene expression over different cell lines was not seen by transcriptome microarray analysis, but in contrast, Reverse Phase Protein Analysis of 250 proteins across 4 cell lines identified Integrin Linked Kinase (ILK) signaling that was functionally confirmed by an ILK inhibitor. We suggest that cancer cells suppressed on SISgel could serve as a model for dormancy and re-awakening to allow for the identification of therapeutic targets for treating micrometastases.
References
[1]
Iozzo RV (1995) Tumor stroma as a regulator of neoplastic behavior. Agonistic and antagonistic elements embedded in the same connective tissue. Lab Invest 73: 157–160.
[2]
Ronnov-Jessen L, Petersen OW, Bissell MJ (1996) Cellular changes involved in conversion of normal to malignant breast: importance of the stromal reaction. Physiol Rev 76: 69–125.
[3]
Vessella RL, Pantel K, Mohla S (2007) Tumor Cell Dormancy: An NCI Workshop Report. Cancer Biol Ther 6.
[4]
Willis L, Alarcon T, Elia G, Jones JL, Wright NA, et al. (2010) Breast cancer dormancy can be maintained by small numbers of micrometastases. Cancer Res 70: 4310–4317.
[5]
Hoffman RM (2008) In vivo real-time imaging of nuclear-cytoplasmic dynamics of dormancy, proliferation and death of cancer cells. Apmis 116: 716–729.
[6]
Talmadge JE, Fidler IJ (2010) AACR centennial series: the biology of cancer metastasis: historical perspective. Cancer Res 70: 5649–5669.
[7]
Leung CT, Brugge JS (2012) Outgrowth of single oncogene-expressing cells from suppressive epithelial environments. Nature.
[8]
Rao JY, Hemstreet GP, Hurst RE, Bonner RB, Jones PL, et al. (1993) Alterations in phenotypic biochemical markers in bladder epithelium during tumorigenesis. Proc Natl Acad Sci U S A 90: 8287–8291.
[9]
Brennan JA, Mao L, Hruban RH, Boyle JO, Eby YJ, et al. (1995) Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck. N Engl J Med 332: 429–435.
[10]
Milojkovic D, Apperley J (2009) Mechanisms of Resistance to Imatinib and Second-Generation Tyrosine Inhibitors in Chronic Myeloid Leukemia. Clin Cancer Res 15: 7519–7527.
[11]
Pohlmann PR, Mayer IA, Mernaugh R (2009) Resistance to Trastuzumab in Breast Cancer. Clin Cancer Res 15: 7479–7491.
[12]
Quesnel B (2008) Dormant tumor cells as a therapeutic target? Cancer Lett 267: 10–17.
[13]
Hurst RE, Kamat CD, Kyker KD, Green DE, Ihnat MA (2005) A novel multidrug resistance phenotype of bladder tumor cells grown on Matrigel or SIS gel. Cancer Lett 217: 171–180.
[14]
Hurst RE, Kyker KD, Bonner RB, Bowditch RG, Hemstreet GP (2003) Matrix-Dependent Plasticity of the Malignant Phenotype of Bladder Cancer Cells. Anticancer Res 23: 3119–3128.
[15]
Orkin RW, Gehron P, McGoodwin EB, Martin GR, Valentine T, et al. (1977) A murine tumor producing a matrix of basement membrane. J Exp Med 145: 204–220.
[16]
Dinney CP, Fishbeck R, Singh RK, Eve B, Pathak S, et al. (1995) Isolation and characterization of metastatic variants from human transitional cell carcinoma passaged by orthotopic implantation in athymic nude mice. J Urol 154: 1532–1538.
[17]
Badylak SF, Record R, Lindberg K, Hodde J, Park K (1998) Small intestinal submucosa: a substrate for in vitro cell growth. J Biomater Sci Polym Ed 9: 863–878.
[18]
Barkan D, Kleinman H, Simmons JL, Asmussen H, Kamaraju AK, et al. (2008) Inhibition of metastatic outgrowth from single dormant tumor cells by targeting the cytoskeleton. Cancer Res 68: 6241–6250.
[19]
Saudemont A, Jouy N, Hetuin D, Quesnel B (2005) NK cells that are activated by CXCL10 can kill dormant tumor cells that resist CTL-mediated lysis and can express B7-H1 that stimulates T cells. Blood 105: 2428–2435.
[20]
O'Reilly MS, Holmgren L, Chen C, Folkman J (1996) Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 2: 689–692.
[21]
Holmgren L, O'Reilly MS, Folkman J (1995) Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1: 149–153.
[22]
Barkan D, Green JE, Chambers AF (2010) Extracellular matrix: a gatekeeper in the transition from dormancy to metastatic growth. Eur J Cancer 46: 1181–1188.
[23]
Dozmorov MG, Kyker KD, Saban R, Knowlton N, Dozmorov IM, et al. (2006) Analysis of the Interaction of Extracellular Matrix and Phenotype of Bladder Cancer Cells. BMC Cancer 6: 12.
[24]
Muschler J, Lochter A, Roskelley CD, Yurchenco P, Bissell MJ (1999) Division of labor among the α6β4 integrin, β1 integrins, and an E3 laminin receptor to signal morphogenesis and β-casein expression in mammary epithelial cells. Mol Biol Cell 10: 2817–2828.
[25]
Hurst RE, Kyker KD, Dozmorov MG, Takemori N, Singh A, et al. (2006) Proteome-level display by 2-dimensional chromatography of extracellular matrix-dependent modulation of the phenotype of bladder cancer cells. Proteome Sci 4: 13.
[26]
Knowlton N, Dozmorov I, Kyker K, Saban R, Cadwell C, et al. (2006) A Template-Driven Gene Selection Procedure. IEE Proceedings–Systems Biology 153: 4–12.
[27]
Amling CL (2001) Diagnosis and management of superficial bladder cancer. Curr Probl Cancer 25: 219–278.
[28]
Hockel M, Dornhofer N (2005) The hydra phenomenon of cancer: why tumors recur locally after microscopically complete resection. Cancer Res 65: 2997–3002.
Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, et al. (2004) Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 5: R80.
[31]
Wettenhall JM, Simpson KM, Satterley K, Smyth GK (2006) affylmGUI: a graphical user interface for linear modeling of single channel microarray data. Bioinformatics 22: 897–899.
[32]
Reiner A, Yekutieli D, Benjamini Y (2003) Identifying differentially expressed genes using false discovery rate controlling procedures. Bioinformatics 19: 368–375.
[33]
Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, et al. (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102: 15545–15550.
[34]
Kanehisa M, Goto S (2000) KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res 28: 27–30.
[35]
Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, et al. (2000) Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 25: 25–29.
